News & Updates

Treatment with apremilast appears safe and effective against mild to moderate plaque psoriasis, according to a recent study.

Ritlecitinib and brepocitinib, both Janus kinase (JAK) inhibitors, show promising efficacy for the treatment of alopecia areata (AA), a new trial has found.

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Patients who received tonsillectomy have a lower risk of psoriasis, reports a study, following adjustment for baseline characteristics, comorbidities, and medical confounders relative to a comparison group.